PPCBD Stock Price, Chart, Stats & News

Propanc Biopharma, Inc. is an Australian biopharmaceutical company focused on developing cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancers. The firm's lead product, PRP, is a formulation in the preclinical phase designed to amplify the anti-cancer effects of multiple enzymes. Propanc engages in research collaborations, including a joint drug discovery program called POP1 with the University of Jaén, and a separate joint initiative with the Universities of Jaén and Granada to investigate changes in genetic and protein expression observed in cancer cells.